Safety and Efficacy of Saxagliptin in Triple Therapy to Treat Subjects With Type 2 Diabetes



Status:Completed
Conditions:Diabetes
Therapuetic Areas:Endocrinology
Healthy:No
Age Range:18 - Any
Updated:4/21/2016
Start Date:June 2012
End Date:January 2015

Use our guide to learn which trials are right for you!

A Multicenter, Randomized, Double-Blind, Placebo Controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of Triple Therapy With Saxagliptin Added to Dapagliflozin in Combination With Metformin Compared to Therapy With Placebo Added to Dapagliflozin in Combination With Metformin in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin and Dapagliflozin

The purpose of this study is to learn if BMS-477118 (Saxagliptin) as part of a triple
combination therapy can improve (decrease) hemoglobin A1c in patients with type 2 diabetes
after 24 weeks of treatment compared to a 2 drug oral antidiabetic therapy. The safety of
this treatment will also be studied.


Inclusion Criteria

1. Signed Written Informed Consent

a) Subjects must be willing and able to give signed and dated written informed
consent.

2. Target Population

1. Subjects with T2DM with inadequate glycemic control, defined as central
laboratory HbA1c ≥ 8.0 and ≤ 11.5% obtained at the screening visit (ie Week -18
visit)

2. Stable metformin therapy for at least 8 weeks prior to screening visit at a dose
≥ 1500 mg per day.

3. C-peptide ≥ 1.0 ng/mL (0.34 nmol/L) at screening visit.

4. BMI ≤ 45.0 kg/m2 at the screening visit.

3. Age and Reproductive Status

1. Men and women, aged ≥ 18 years old at time of screening visit.

2. Women of childbearing potential (WOCBP) must be using an acceptable method of
contraception to avoid pregnancy throughout the study in such a manner that the
risk of pregnancy is minimized. See Section 3.3.3 for the definition of WOCBP.

3. WOCBP must have a negative serum or urine pregnancy test (minimum sensitivity 25
IU/L or equivalent units of HCG) within 24 hours prior to the start of
investigational product.

4. Women must not be breastfeeding

5. Sexually active fertile men must use effective birth control if their partners
are WOCBP.

Exclusion Criteria

1. Target Disease Exceptions

1. History of diabetes insipidus

2. Symptoms of poorly controlled diabetes that would preclude participation in this
trial including but not limited to marked polyuria and polydipsia with greater
than 10% weight loss during the three months prior to screening, or other signs
and symptoms.

3. History of diabetic ketoacidosis or hyperosmolar nonketotic coma.

2. Medical History and Concurrent Diseases

1. History of bariatric surgery or lap-band procedure within 12 months prior to
screening.

2. Any unstable endocrine, psychiatric or rheumatic disorders as judged by the
Investigator.

3. Subject who, in the judgment of the investigator, may be at risk for dehydration
or volume depletion that may affect the interpretation of efficacy or safety
data and concomitant use of loop diuretics in countries where this is not
recommended as per the Dapagliflozin label.

4. Subject is currently abusing alcohol or other drugs or has done so within the
last 6 months.

Acute Vascular Event:

5. Uncontrolled hypertension defined as systolic blood pressure (SBP) ≥ 160 mmHg
and/or diastolic blood pressure (DBP) ≥ 100 mmHg.

Note: Subjects with SBP ≥ 160mmHg and < 180mmHg or a DBP ≥ 100 mmHg and <
110mmHg will be able to enter the lead-in period, provided their hypertension
treatment is adjusted as deemed appropriate by the investigator. These subjects
cannot be randomized if their blood pressure remains with SBP ≥ 160 mmHg or DBP
≥ 100 mmHg measured at Day 1.

6. Cardiovascular Disease within 3 months of the screening visit [ie myocardial
infarction, cardiac surgery or revascularization (CABG/PTCA), unstable angina,
stroke or transient ischemic attack (TIA)].

7. Congestive heart failure as New York Association (NYHA) class IV (see Appendix
1), unstable or acute congestive heart failure. Note: eligible patients with
congestive heart failure, especially those who are on diuretic therapy, should
have careful monitoring of their volumes status throughout the study.

Renal Diseases:

8. Moderate or severe impairment of renal function [defined as eGFR < 60
mL/min/1.73 m2 (estimated by MDRD) or serum creatinine (Scr) ≥ 1.5 mg/dL in
males or ≥ 1.4 mg/dL in females.]

9. Conditions of congenital renal glucosuria

Hepatic Diseases:

10. Significant hepatic disease, including, but not limited to, chronic active
hepatitis and/or severe hepatic insufficiency, including subjects with ALT
and/or AST > 3x ULN and or Total Bilirubin > 2.5 x ULN.

Hematological and Oncological Disease/Conditions

11. History of hemoglobinopathy, with the exception of sickle cell trait (SA) or
thalassemia minor; or chronic or recurrent hemolysis.

12. Malignancy within 5 years of the screening visit (with the exception of treated
basal cell or treated squamous cell carcinoma)

13. Known immunocompromised status, including but not limited to, individuals who
have undergone organ transplantation or who are positive for the human
immunodeficiency virus.

14. Donation of blood or blood products to a blood bank, blood transfusion, or
participation in a clinical study requiring withdrawal of > 400 mL of blood
during the 6 months prior to the screening visit.

Prohibited treatment and therapies

15. Administration of any antihyperglycemic therapy, other than metformin, for more
than 14 days (consecutive or not) during the 12 weeks prior to screening, as
well as previous participation in any DPP-4 or SGLT-2 inhibitor trial is an
exclusion criterion.

16. Current treatment with potent cytochrome P450 3A4/5 inhibitors (in countries
where dose adjustment would be required by the saxagliptin label).

17. Administration of any other investigational drug or participation in any
interventional clinical studies within 30 days of planned screening to this
study. Subjects who failed to satisfy all eligibility criteria at screening and
did not enter the lead-in or open-label period in CV181-169 or MB102-129 studies
specifically, do not need to wait 30 days.

3. Physical and Laboratory Test Findings

1. Hemoglobin ≤ 11.0 g/dL (110 g/L) for men; hemoglobin ≤ 10.0 g/dL (100 g/L) for
women

2. Male subjects with microscopic hematuria present at Week -18 or Week -16 AND no
common cause that can be confirmed. Male subjects with a confirmed common cause
can be entered into the open-label phase with a documented negative result for
hematuria microscopic urinalysis performed by the central laboratory.

NOTE: Female subjects with hematuria can be entered into the open-label phase
and be randomized, but should be investigated according to local standards and
best clinical practices. (See Appendix 3)

3. Other central laboratory test findings:

- Abnormal free T4 values. Abnormal thyroid stimulating hormone (TSH) value
at screening will be further evaluated by free T4. Subjects with abnormal
free T4 values will be excluded.

- Positive for hepatitis B surface antigen

- Positive for anti-hepatitis C virus antibody

4. Allergies and Adverse Drug Reaction

a) Subjects who have contraindications to therapy as outlined in the saxagliptin and
dapagliflozin Investigator Brochure, the local saxagliptin or dapagliflozin package
insert or the local metformin package insert, including current treatment with potent
cytochrome P450 3A4/5 inhibitors (in countries where dose adjustment would be
required by the local saxagliptin label).

5. Sex and Reproductive Status

a) Women who are pregnant

6. Other Exclusion Criteria

1. Prisoners or subjects who are involuntarily incarcerated.

2. Subject who are compulsorily detained for treatment of either a psychiatric or
physical (eg, infectious disease) illness.
We found this trial at
35
sites
Bristol, Tennessee 37620
?
mi
from
Bristol, TN
Click here to add this to my saved trials
1720 2nd Ave S
Birmingham, Alabama 35233
(205) 934-4011 
University of Alabama at Birmingham The University of Alabama at Birmingham (UAB) traces its roots...
?
mi
from
Birmingham, AL
Click here to add this to my saved trials
304 Northeast 1st Street
Chiefland, Florida 32626
?
mi
from
Chiefland, FL
Click here to add this to my saved trials
2010 Wilshire Boulevard
Los Angeles, California 90057
213-413-2500
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Charlotte, North Carolina 28262
?
mi
from
Charlotte, NC
Click here to add this to my saved trials
Cincinnati, Ohio 45219
?
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Columbia, South Carolina 29204
?
mi
from
Columbia, SC
Click here to add this to my saved trials
Coral Gables, Florida 33134
?
mi
from
Coral Gables, FL
Click here to add this to my saved trials
Corpus Christi, Texas 78404
?
mi
from
Corpus Christi, TX
Click here to add this to my saved trials
Evansville, Indiana 47714
?
mi
from
Evansville, IN
Click here to add this to my saved trials
Evansville, Indiana 47714
?
mi
from
Evansville, IN
Click here to add this to my saved trials
Golden, Colorado 80401
?
mi
from
Golden, CO
Click here to add this to my saved trials
Hialeah, Florida 33012
?
mi
from
Hialeah, FL
Click here to add this to my saved trials
Huntington Beach, California 92647
?
mi
from
Huntington Beach, CA
Click here to add this to my saved trials
?
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Jacksonville, Florida 32277
?
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Las Vegas, Nevada 89128
?
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Lomita, California 90717
?
mi
from
Lomita, CA
Click here to add this to my saved trials
Los Angeles, California 90023
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Mesa, Arizona 85203
?
mi
from
Mesa, AZ
Click here to add this to my saved trials
?
mi
from
Mesa, AZ
Click here to add this to my saved trials
Miami, Florida 33126
?
mi
from
Miami, FL
Click here to add this to my saved trials
Moncton, New Brunswick
?
mi
from
Moncton,
Click here to add this to my saved trials
Muscle Shoals, Alabama 35662
?
mi
from
Muscle Shoals, AL
Click here to add this to my saved trials
Myrtle Beach, South Carolina 29588
?
mi
from
Myrtle Beach, SC
Click here to add this to my saved trials
Nashua, New Hampshire 03063
?
mi
from
Nashua, NH
Click here to add this to my saved trials
Nashville, Tennessee 37212
?
mi
from
Nashville, TN
Click here to add this to my saved trials
New Hyde Park, New York 11042
?
mi
from
New Hyde Park, NY
Click here to add this to my saved trials
?
mi
from
North Massapequa, NY
Click here to add this to my saved trials
?
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Phoenix, Arizona 85282
?
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Saint Louis, Missouri 63141
?
mi
from
Saint Louis, MO
Click here to add this to my saved trials
?
mi
from
Vista, CA
Click here to add this to my saved trials
West Hills, California 91307
?
mi
from
West Hills, CA
Click here to add this to my saved trials
Zanesville, Ohio 43701
?
mi
from
Zanesville, OH
Click here to add this to my saved trials